XBI is a biotech-focused ETF offering equal-weight exposure to U.S. biotechnology companies. The SPDR S&P Biotech ETF tracks the performance of the S&P Biotechnology Select Industry Index. XBI ...

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...

Tobi is a crypto writer at Investopedia. He aims to simplify the complex concepts of blockchain and cryptocurrencies for the masses. Julie Bang/ Investopedia More people need better medicines, and ...

If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

Medicare’s new GLP-1 Bridge program boosts seniors’ access to weight-loss drugs through 2027—see top GLP-1 and biotech stocks to watch now.

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

If you are a Class 12 science student, chances are you have come across this question more than once. Should you choose Pharmacy or Biotechnology? Both sound promising. Both fall under life sciences.